Home - Gastroenterology Advisor
Colonoscopy Prep and Other Quality Indicators for CRC Screening From ACG/ASGE. The American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy Quality Task force have released updated guidance on quality indicators for colonoscopy.
Clinician Insights on How to Manage Semaglutide-Induced …
Sep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
Sep 1, 2023 · There were no reports of gastroparesis in the study. 1. While semaglutide and other GLP-1 agonists cause adverse events, such as nausea, vomiting, diarrhea, and a range of other GI symptoms, these effects of delayed gastric emptying are reported to be reduced after 20 weeks of use. 2. [T]here are some cases where gastroparesis may resolve if ...
Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in …
1 day ago · HealthDay News — For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications, according to a study published online Oct. 24 in Alzheimer’s & Dementia.. William Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted ...
Gastroparesis Awareness Month: Updated Guidelines to Treat …
Aug 19, 2022 · The American College of Gastroenterology (ACG) released updated clinical guidelines on managing gastroparesis (GP). The new recommendations were published in The American Journal of Gastroenterology.. GP is characterized by delayed gastric emptying (GE) of solid food in the absence of mechanical obstruction.
GLP-1 RA Medications in Established GERD Lowers Mortality Risk
Oct 29, 2024 · Patients with a history of gastroesophageal reflux disease (GERD) who initiate treatment with glucagonlike peptide-1 receptor agonist (GLP-1RA) medications are at lower risk for mortality and proton pump inhibitor (PPI) initiation, according to study results presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course, held in Philadelphia ...
Gastric Intestinal Metaplasia: 2020 AGA Guidelines
Mar 12, 2020 · 5. Gupta S et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158 (3):693-702. 6. Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia—natural history and clinical outcomes. Gastroenterology. 2020;158 (3):705-731. 7.
Upper GI Tract Disorders Treated With P-CABs: AGA Clinical …
October 25, 2024. The American Gastroenterological Association (AGA) has released a clinical practice update for managing upper gastrointestinal (GI) tract disorders with potassium-competitive acid blockers (P-CABs). The new guidance was published in Gastroenterology.
Novel Drug Tradipitant Effective, Safe for Treatment of Nausea in ...
Oct 29, 2021 · Tradipitant appears to be an effective and safe treatment option for gastroparesis symptoms, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held from October 22 to 27, 2021, in Las Vegas, Nevada and virtually.
Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
2 days ago · HealthDay News — For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo, according to a study published in the Oct. 31 issue of the New England Journal of Medicine.. Henning Bliddal, M.D., from the Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, and ...